Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Indonesian Journal of Pharmacology and Therapy
Mustikawati, Maria Sri Ayu
Unknown Affiliation
Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Effectiveness and Safety Comparison of Clozapine-Haloperidol with Clozapine-Risperidon Regimen in Schizophrenia Inpatients at Prof. Dr. Soerojo Magelang Mental Hospital Mustikawati, Maria Sri Ayu; Budiman, Bambang Hastha Yoga Legowo; Ikawati, Zullies
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 15, No 2
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.96818

Abstract

Background: Schizophrenia treatment uses drugs from the antipsychotic group. Antipsychotics combination of clozapine-haloperidol and clozapine-risperidone are widely used in schizophrenia inpatients. Clozapine is often used in combination with haloperidol and risperidone (high-potency antipsychotic) to enhance the blockade of D2 receptors.Objectives: To compare the effectiveness and safety of the clozapine-haloperidol regimen with clozapine-risperidone used by schizophrenia inpatients.Methods: The research design was retrospective cohort observational. Data collection based on medical records of inpatients diagnosed with schizophrenia at Prof. Dr. Soerojo Magelang Mental Hospital in January 2021 - June 2023. The subjects were 142 people (71 people in both groups). Effectiveness was assessed by the difference in pre and post-PANSS-EC scores, as well as clinical improvement through the final PANSS-EC score. Meanwhile, safety was evaluated based on the incidence of drug side effects. The data was then analyzed statistically.Results: The average PANSS-EC score decrease was 10 ± 5.53 in the clozapine-haloperidol group and 11 ± 5.70 in clozapine-risperidone group. Nonetheless, there was no meaningful contrast between them in terms of PANSS-EC difference (p=0.326), or improvement in clinical condition by the final PANSS-EC score (p=0.111). Also, there was no meaningful distinction in the incidence of adverse drug events (p=0.422).  However, extrapyramidal syndrome, the most frequent side effect (18 out of 40 cases), had a significant difference with the clozapine-haloperidol group having the most cases (p=0.044).Conclusion: Both regimens are interchangeable in clinical practice. But clozapine-risperidone is better tolerated regarding extrapyramidal side effects.
Safety profile between fluoxetine and sertraline as antidepressants for pregnant women with depression disorder Dewa Ayu Sri Handani; Mustikawati, Maria Sri Ayu; Parwatininghati, Ni Putu; Zulkarnaen; Akuba, Jusnita
Indonesian Journal of Pharmacology and Therapy Vol 4 No 1 (2023)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.3237

Abstract

Depression disorders are common in women of productive age, especially during pregnancy and peripartum period. Making a decision on the choosing of antidepressants is associated to the biggest concern about the risk of birth defects and major anomalies of their exposure. Decisions of antidepressant use not only involve considering the risks of medications exposure, but also the risks of untreated depression during pregnancy. Evaluation of the safety profile of selective reuptake inhibitors (SSRIs) which are commonly prescribed during pregnancy therefore urgently needed. This review aimed to compare two widely used SSRIs i.e. fluoxentine and sertraline as antidepressants for pregnant women with depression disorder. It is found that sertraline has more positive effects and more safe. Sertraline is well tolerated in pregnant women and breastfeeding mothers with depression disorder.
Co-Authors Akuba, Jusnita Budiman, Bambang Hastha Yoga Legowo Dewa Ayu Sri Handani Parwatininghati, Ni Putu Zulkarnaen